Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration

Journal of Clinical Immunology

Volumn 28, Issue 3, 2008, Pages 263-267

  Quinti, Isabella ^a   Soresina, Annarosa ^b   Agostini, Carlo ^c   Spadaro, Giuseppe ^d   Matucci, Andrea ^e   Sfika, Ifigeneia ^a   Martini, Helene ^a   Borghese, Federica ^a   Guerra, Andrea ^a   Alessandra, Vultaggio ^e   Visentini, Marcella ^a   Plebani, Alessandro ^b   Fiorilli, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adverse reactions; Common variable immunodeficiency; Intravenous immunoglobulins; Subcutaneous immunoglobulins

Indexed keywords

CHLORPHENIRAMINE; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; SUBCUVIA;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BACKACHE; CHILL; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CYANOSIS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; FEVER; HUMAN; HYPOTENSION; LOW DRUG DOSE; MUCOSA INFLAMMATION; NAUSEA; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; COMMON VARIABLE IMMUNODEFICIENCY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 43049114886     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-007-9169-9     Document Type: Article

References (20)

1. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med. 1991;325:110-7.
2. AAACI. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Aller Clin Immunol. 2006;117(Suppl.):526-53.
3. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Safety. 1999;9:254-62.
4. de Albuquerque Campos R, Sato MN, da Silva Duarte AJ. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol. 2000;20:77-82.
5. Quinti I, Pierdominici M, Marziali M, Giovannetti A, Donnanno S, Chapel H, Bjorkander J, Aiuti F, European Study Group for the Surveillance of Immunoglobulin Safety. European surveillance of immunoglobulin safety-results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries. Clin Immunol. 2002;104:231-6.
6. Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol. 2003;133:247.
7. Tcheurekjian H, Martin J, Kobayashi R, Wasserman R, Hostoffer R. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states. Allergy Asthma Proc. 2006;27:532-6.
8. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006;6:535-42.
9. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94-100.
10. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol. 1994;97(Suppl.):79-83.
11. Schiff RI, Williams LW, Nelson RP, Buckley RH, Burks W, Good RA. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol. 1997;17:21-8.
12. Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini C, Claudio P, Franco D, Maria Pesce A, Borghese F, Guerra A, Rondelli R, Plebani A, Italian Primary Immunodeficiency Network. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol. 2007;27:308-16.
13. Plebani A, Lougaris V, Soresina A, Meini A, Zunino F, Losi CG, Gatta R, Cattaneo G, Nespoli L, Marinoni M, Capolunghi F, Vivarelli M, Quinti I, Carsetti R. A novel immunodeficiency characterized by the exclusive presence of transitional B cells unresponsive to CpG. Immunology. 2007;121:183-8.
14. Horn J, Thon V, Bartonkova D, Salzer U, Warnatz K, Michael Schlesier M, Peter HH, Grimbacher B. Anti-IgA antibodies in ommon Variable Immunodeficiency (CVID): Diagnostic workup and therapeutic strategy. Clin Immunol. 2007;122:156-62.
15. Immune Deficiency Foundation patient survey. Available at: http://www.primaryimmune.org/pid/survey.htm. Accessed November 1, 2005
16. Sundin U, Nava S, Hammarstrom L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol. 1998;112:341-6.
17. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94-100.
18. Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, Hammarstrom L, Jacobsen MB, Jonsson E, Moller G. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345:365-9.
19. Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Bock A, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114:936-42.
20. Eijkhout HW, van den Broek PJ, van der Meer JWM. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med. 2003;61:213-7.